Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).

Luis Costa,Daniel Castellano,Javier Puente,Lidia Martin,Urbano Anido,Jessica Gomez,Ignacio Duran

Exploring the synergistic effects of cabozantinib (cabo) and a programmed cell death protein 1 (PD1) inhibitor in metastatic renal cell carcinoma (mRCC) with artificial intelligence (AI).

2021

Luis Costa
Daniel Castellano
Javier Puente
Lidia Martin
Urbano Anido
Jessica Gomez
Ignacio Duran

336Background: Nonclinical and clinical data suggest that cabo with a PD1 inhibitor provides synergistic antitumor activity in patients with mRCC, possibly by a cabo-induced switch to an immunoperm...

Keywords:

Cancer research
antitumor activity
in patient
Cabozantinib
Renal cell carcinoma
PD1 Inhibitor
Medicine
Programmed cell death 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations